HOOKIPA Pharma Inc.
hookipapharma.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q1 FY2025 10-Q, filed May 15, 2025. Its latest SEC filing is a 4 from Oct 9, 2025.
10-Q for Q1 FY2025, filed May 15, 2025
The sections below describe the company as of the FY2024 annual report.
What Did They Do?
Develops immune therapies using engineered arenaviruses for cancer and infectious diseases, including hepatitis B and HIV programs conducted with a pharmaceutical partner.
10-K for FY2024, filed Feb 28, 2025
How Did They Make Money?
Pharmaceutical partners pay upfront fees and reimburse research and development work as it progresses; they may also make payments at development milestones, and Gilead's agreement provides for royalties on product sales.
10-K for FY2024, filed Feb 28, 2025Under the collaboration and license agreement with Gilead (as amended and restated, the “Gilead Collaboration Agreement”), the parties…View ↗
Under the research collaboration and license agreement with Roche (the “Roche Collaboration Agreement”), the Company agreed to conduct…View ↗
Under the Gilead Collaboration Agreement and historically under the Roche Collaboration Agreement prior to termination, the Company incurs…View ↗
Research and development milestonesView ↗
$43.9M
-
10-K for FY2024, filed Feb 28, 2025
$43.9M ↗
Who Were Their Customers?
Works directly with pharmaceutical partners Gilead on hepatitis B and HIV research and, until its agreement ended, Roche on cancer programs.
10-K for FY2024, filed Feb 28, 2025Under the collaboration and license agreement with Gilead (as amended and restated, the “Gilead Collaboration Agreement”), the parties…View ↗
Under the research collaboration and license agreement with Roche (the “Roche Collaboration Agreement”), the Company agreed to conduct…View ↗
We are collaborating with Gilead to research arenavirus functional cures for chronic Hepatitis B and HIV infections under a Collaboration…View ↗
How Were They Changing?
- Net income
-
Sources
10-Q for Q1 FY2025, filed May 15, 2025
−$15.4MView ↗
- ▼ Now a loss
- vs $14.4M in Q1 FY2024
-
Jul 18, 2025
Announced plans to delist and deregister its common stock
It also said it would seek approval for the Gilead asset sale and the company’s dissolution and liquidation.
Sources
8-K, filed Jul 18, 2025
On July 18, 2025, HOOKIPA Pharma Inc. (the “Company”) delivered formal notice to The Nasdaq Stock Market LLC of its intention to…View ↗
-
May 22, 2025
Agreed to sell HB-400 and certain HB-500 assets to Gilead
Gilead agreed to pay up to $10,000,000, subject to stockholder approval and completion of transfer stages.
Sources
8-K, filed May 22, 2025
On May 21, 2025, (the “Execution Date”) HOOKIPA Pharma Inc., a Delaware corporation (the “Company”), Hookipa Biotech GmbH, the Company’s…View ↗
Grew. Revenue grew 2.2x in 4 years, from $19.6M in FY2020 to $43.9M in FY2024, about 22% a year.
Broader cancer targets
The earlier report centered its oncology discussion on HPV-positive cancers; the latest also describes an immunotherapy program for KRAS-mutated cancers.
10-K for FY2021, filed Mar 24, 2022 10-K for FY2024, filed Feb 28, 2025We are building a proprietary immuno-oncology pipeline by targeting oncoviral cancer antigens, self-antigens and next-generation antigens.…View ↗
HB-700 is a novel, next-generation multi-KRAS mutant-targeting, investigational immunotherapy for the treatment of KRAS mutated cancers…View ↗
Different infectious disease programs
The earlier report highlighted a CMV vaccine candidate for people awaiting kidney transplants; the latest describes hepatitis B and HIV programs developed with Gilead.
10-K for FY2021, filed Mar 24, 2022 10-K for FY2024, filed Feb 28, 2025We are building a proprietary immuno-oncology pipeline by targeting oncoviral cancer antigens, self-antigens and next-generation antigens.…View ↗
Additionally, we are developing infectious disease therapies in partnership with other companies. Our Hepatitis B (“HBV”) program, HB-400…View ↗
Who Did They Compete With?
Competes with Elicio Therapeutics, BioNTech, PDS Biotech, TCR Cure, Transgene, Ultimovacs, Abalos, Adaptimmune, CureVac, Merck &, Moderna, Novartis, Replimune Group, Roche, and Turnstone Biologics
10-K for FY2024, filed Feb 28, 2025Our competitors in the development of product candidates in our lead immunooncology indication of therapies for mutated KRAS and HPV+…View ↗
Loading...
